Drug Type Small molecule drug |
Synonyms Exentra, 엑센트라콜드연질캡슐 |
Action inhibitors, antagonists, agonists |
Mechanism COX inhibitors(Cyclooxygenases inhibitors), H1 receptor antagonists(Histamine H1 receptor antagonists), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (03 Mar 2026), |
Regulation- |
Molecular FormulaC20H23ClN2O4 |
InChIKeyDBAKFASWICGISY-BTJKTKAUSA-N |
CAS Registry113-92-8 |
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Common Cold | South Korea | 03 Mar 2026 |





